Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

Masato Furuhashi 1, Ichiro Sakuma 2, Takeshi Morimoto 3, Yukimura Higashiura 4, Akiko Sakai 4, Megumi Matsumoto 4, Mio Sakuma 3, Michio Shimabukuro 5, Takashi Nomiyama 6, Osamu Arasaki 7, Koichi Node 8, Shinichiro Ueda 9

Main idea: Anagliptin decreases serum FABP4 concentration independent of change in hemoglobin A1c or LDL-C in patients with type 2 diabetes mellitus and dyslipidemia who are on statin therapy.

Abstract

Background: Fatty acid-binding protein 4 (FABP4) acts as a novel adipokine. Elevated FABP 4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibly leading to a drug class effect and each drug effect.

Aim and methods: Study looked at effects of statin therapy on FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular events. Study used data from REASON trial, which followed patients for 52 weeks.

Results: Serum FABP4 level was significantly decreased by 7.9% by treatment with anagliptin and was not significantly decreased with treatment with sitagli leptin. Change in FABp4 level independently associated with changes in waist circumference and creatinine.

Source NIH